Literature DB >> 9326274

Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters.

A J Eshleman1, E Stewart, A K Evenson, J N Mason, R D Blakely, A Janowsky, K A Neve.   

Abstract

To determine if catechol-O-methyltransferase (COMT) metabolizes catecholamines within cell lines used for heterologous expression of plasmalemmal transporters and alters the measured characteristics of 3H-substrate transport, the uptake of monoamine transporter substrates was assessed in three cell lines (C6 glioma, L-M fibroblast, and HEK293 cells) that had been transfected with the recombinant human transporters. Uptake and cellular retention of 3H-catecholamines was increased by up to fourfold by two COMT inhibitors, tropolone and Ro 41-0960, with potencies similar to those for inhibition of COMT activity, whereas the uptake of two transporter substrates that are not substrates for COMT, [3H]serotonin and [3H]MPP+, was unaffected. Direct measurement of monoamine substrates by HPLC confirmed that tropolone (1 mM) increased the retention of the catecholamines dopamine and norepinephrine, but not the retention of serotonin in HEK293 cells. Saturation analysis of the uptake of [3H]dopamine by C6 cells expressing the dopamine transporter demonstrated that tropolone (1 mM) decreased the apparent Km of transport from 0.61 microM to 0.34 microM without significantly altering the maximal velocity of transport. These data suggest that endogenous COMT activity in mammalian cells may alter neurotransmitter deposition and thus the apparent kinetic characteristics of transport.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326274     DOI: 10.1046/j.1471-4159.1997.69041459.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Nitric oxide inhibits uptake of dopamine and N-methyl-4-phenylpyridinium (MPP+) but not release of MPP+ in rat C6 glioma cells expressing human dopamine transporter.

Authors:  Bo-Jin Cao; Maarten E A Reith
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Antidepressants Accumulate in Lipid Rafts Independent of Monoamine Transporters to Modulate Redistribution of the G Protein, Gαs.

Authors:  Samuel J Erb; Jeffrey M Schappi; Mark M Rasenick
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

3.  Neurotransmitter and psychostimulant recognition by the dopamine transporter.

Authors:  Kevin H Wang; Aravind Penmatsa; Eric Gouaux
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

4.  Disruption of lipid-raft localized Gαs/tubulin complexes by antidepressants: a unique feature of HDAC6 inhibitors, SSRI and tricyclic compounds.

Authors:  Harinder Singh; Nathan Wray; Jeffrey M Schappi; Mark M Rasenick
Journal:  Neuropsychopharmacology       Date:  2018-02-05       Impact factor: 7.853

5.  Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment.

Authors:  H Hastrup; A Karlin; J A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

6.  Catechol-O-methyltransferase activity in CHO cells expressing norepinephrine transporter.

Authors:  E Percy; D M Kaye; G W Lambert; S Gruskin; M D Esler; X J Du
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

7.  Conformational changes in dopamine transporter intracellular regions upon cocaine binding and dopamine translocation.

Authors:  Yvette Dehnes; Jufang Shan; Thijs Beuming; Lei Shi; Harel Weinstein; Jonathan A Javitch
Journal:  Neurochem Int       Date:  2014-02-24       Impact factor: 3.921

8.  Cocaine acts as an apparent competitive inhibitor at the outward-facing conformation of the human norepinephrine transporter: kinetic analysis of inward and outward transport.

Authors:  N Chen; J B Justice
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

9.  Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.

Authors:  Steven P Presgraves; Tariq Ahmed; Sabine Borwege; Jeffrey N Joyce
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.978

10.  Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.

Authors:  Jeffrey N Joyce; Cheryl Woolsey; Han Ryoo; Sabine Borwege; Diane Hagner
Journal:  BMC Biol       Date:  2004-10-11       Impact factor: 7.431

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.